When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OVID - Ovid Therapeutics Is Quickly Approaching A Transformational Valuation Milestone
Ovid Therapeutics Inc.
At $6.75/share, Ovid Therapeutics Inc. (OVID) has a fully diluted market cap of ~$430MM. After recent receipt of $20MM as an upfront payment from a new commercial partner, OVID has an approximate cash balance of $50MM. With $0 debt, OVID's enterprise valuation is therefore approximately $380MM. Should OVID's Phase 3 clinical trial of OV101 lead to FDA approval to treat Angelman Syndrome (perhaps as soon as Q42021), OV101 could be a Blockbuster therapy with estimated potential peak annual revenues well in excess of $1 billion. OVID expects to release OV101's Phase 3 top-line